CDER “Comprehensive” Reorganization To Follow After CBER-CDER Merger
This article was originally published in The Tan Sheet
Executive Summary
CDER plans to reorganize into indication-based divisions following the merger between FDA's drug and biologics centers, Office of New Drugs Director John Jenkins, MD, said during the Biotechnology Industry annual meeting in Washington, D.C. June 24